Candriam S.C.A. Atara Biotherapeutics, Inc. Transaction History
Candriam S.C.A.
- $15.4 Billion
- Q1 2024
Shares
3 transactions
Others Institutions Holding ATRA
# of Institutions
87Shares Held
85MCall Options Held
18.4KPut Options Held
51.3K-
Eco R1 Capital, LLC San Francisco, CA10.2MShares$78.4 Million0.2% of portfolio
-
Redmile Group, LLC San Francisco, CA9.26MShares$71.4 Million0.25% of portfolio
-
Black Rock Inc. New York, NY6.83MShares$52.7 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC6.58MShares$50.7 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il6.51MShares$50.2 Million0.0% of portfolio
About Atara Biotherapeutics, Inc.
- Ticker ATRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,362,304
- Market Cap $728M
- Description
- Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...